These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 34198419)
1. Four-lncRNA immune prognostic signature for triple-negative breast cancer Running title: Immune lncRNAs predict prognosis of TNBC. Li YX; Wang SM; Li CQ Math Biosci Eng; 2021 May; 18(4):3939-3956. PubMed ID: 34198419 [TBL] [Abstract][Full Text] [Related]
2. A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer. Wu J; Cai Y; Zhao G; Li M J Clin Lab Anal; 2021 Jun; 35(6):e23779. PubMed ID: 33934391 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer. Fan CN; Ma L; Liu N J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer. Yang R; Xing L; Wang M; Chi H; Zhang L; Chen J Cell Physiol Biochem; 2018; 50(2):473-488. PubMed ID: 30308479 [TBL] [Abstract][Full Text] [Related]
5. Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer. Zhao Y; Song Y; Zhang Y; Ji M; Hou P; Sui F Mol Cell Probes; 2023 Dec; 72():101940. PubMed ID: 37871689 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments. Zhang M; Zhang F; Wang J; Liang Q; Zhou W; Liu J J Transl Med; 2024 May; 22(1):423. PubMed ID: 38704606 [TBL] [Abstract][Full Text] [Related]
7. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184 [TBL] [Abstract][Full Text] [Related]
8. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. Ma W; Zhao F; Yu X; Guan S; Suo H; Tao Z; Qiu Y; Wu Y; Cao Y; Jin F J Transl Med; 2020 Nov; 18(1):442. PubMed ID: 33225954 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of long non-coding RNAs in triple negative breast cancer: A PRISMA-compliant meta-analysis. Zhang S; Ma F; Xie X; Shen Y Medicine (Baltimore); 2020 Sep; 99(37):e21861. PubMed ID: 32925722 [TBL] [Abstract][Full Text] [Related]
10. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer. Peng Y; Wang H; Huang Q; Wu J; Zhang M J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063 [TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Novel Stemness-Index-Related Long Noncoding RNA Signature for Breast Cancer Based on Weighted Gene Co-Expression Network Analysis. Qian D; Qian C; Ye B; Xu M; Wu D; Li J; Li D; Yu B; Tao Y Front Genet; 2022; 13():760514. PubMed ID: 35273635 [No Abstract] [Full Text] [Related]
12. Comprehensive analysis of N Zhu HX; Lu WJ; Zhu WP; Yu S J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346 [TBL] [Abstract][Full Text] [Related]
13. Prognostic risk model under the immune-associated long chain non-coding ribonucleic acid and its application in survival prognosis assessment of patients with breast cancer. Yang S; Wang Q Sci Rep; 2024 Aug; 14(1):18928. PubMed ID: 39147766 [TBL] [Abstract][Full Text] [Related]
14. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma. Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168 [No Abstract] [Full Text] [Related]
15. A novel prognostic model associated with the overall survival in patients with breast cancer based on lipid metabolism-related long noncoding RNAs. Shi GJ; Zhou Q; Zhu Q; Wang L; Jiang GQ J Clin Lab Anal; 2022 Jun; 36(6):e24384. PubMed ID: 35441740 [TBL] [Abstract][Full Text] [Related]
16. LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer. Lv M; Xu P; Wu Y; Huang L; Li W; Lv S; Wu X; Zeng X; Shen R; Jia X; Yin Y; Gu Y; Yuan H; Xie H; Fu Z Oncotarget; 2016 Mar; 7(11):13047-59. PubMed ID: 26910840 [TBL] [Abstract][Full Text] [Related]
17. Identification of cuproptosis-related miRNAs in triple-negative breast cancer and analysis of the miRNA-mRNA regulatory network. Wang Y; Wang J; Jiang J; Zhang W; Sun L; Ge Q; Li C; Li X; Li X; Shi S Heliyon; 2024 Apr; 10(7):e28242. PubMed ID: 38601669 [TBL] [Abstract][Full Text] [Related]
18. Identification of HCG18 and MCM3AP-AS1 That Associate With Bone Metastasis, Poor Prognosis and Increased Abundance of M2 Macrophage Infiltration in Prostate Cancer. Chen Y; Chen Z; Mo J; Pang M; Chen Z; Feng F; Xie P; Yang B Technol Cancer Res Treat; 2021; 20():1533033821990064. PubMed ID: 33596783 [TBL] [Abstract][Full Text] [Related]
19. Novel Long Non-coding RNA Markers for Prognostic Prediction of Patients with Bladder Cancer. Li WX; Zhang YL Chin Med Sci J; 2020 Sep; 35(3):239-247. PubMed ID: 32972501 [TBL] [Abstract][Full Text] [Related]
20. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer. Wang J; Shen C; Dong D; Zhong X; Wang Y; Yang X Int Immunopharmacol; 2021 Jan; 90():107146. PubMed ID: 33189610 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]